The development of immunotherapies for neuroblastoma remains challenging owing to the low immunogenicity of neuroblastoma cells, as reflected by the low expression of one of the main triggers of immune recognition, the major histocompatibility complex class I (MHC-I). Cornel et al. showed that epigenetic modulation of neuroblastoma cells with a histone deacetylase inhibitor can boost the expression of major histocompatibility complex class I, among other immune receptors, priming their recognition by T- and natural killer cells. By leveraging the developmentally related aberrant epigenetic landscapes of neuroblastoma, these discoveries pave the way to overcome a major limitation in the field of neuroblastoma immunotherapy.
Jiménez C, Moreno L, Segura MF. Epigenetic therapies for neuroblastoma: Immunogenicity awakens. Mol Oncol. 2023 May;17(5):718–21.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/9868
The following license files are associated with this item: